Namrata Vijayvergia

Also affiliated with Temple University Health System

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors”.

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.7

N/A

0.561DataRank · unranked

41 citations

Greg Yothers, Osama E. Rahma, Theodore S. Hong, Marcia M. Russell, Y. Nancy You +14 more

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.8

N/A

0DataRank · unranked

32 citations

Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker +10 more

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Hormone and Metabolic Research(2022)10.1055/a-1908-7790

N/A

0DataRank · unranked

14 citations

Namrata Vijayvergia, Jian Yu, Joanna Kłubo-Gwieździńska, Christian A. Koch, Sriram Gubbi

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4185

N/A

0DataRank · unranked

0 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Shaalan Beg +9 more

The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad121

N/A

0DataRank · unranked

9 citations

Barbara Burtness, May Cho, Jaydira Del Rivero, Deborah B. Doroshow, Kathryn Hitchcock +12 more

Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4133

N/A

0DataRank · unranked

0 citations

Elizabeth A. Handorf, Pamela L. Kunz, Emel Alkım, Lauren M. Burke, Paul J. Catalano +10 more

First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer

Clinical Colorectal Cancer(2020)10.1016/j.clcc.2020.08.003

N/A

0DataRank · unranked

6 citations

Crystal S. Denlinger, Namrata Vijayvergia, Steven J. Cohen, Igor Astaturov, Efrat Dotan +14 more

Gastroenteropancreatic Neuroendocrine Tumors

Gastroenterology(2025)10.1053/j.gastro.2025.07.004

N/A

0DataRank · unranked

4 citations

Linda Lee, Bryson W. Katona, Namrata Vijayvergia

Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer

JCO Clinical Cancer Informatics(2021)10.1200/cci.20.00117

N/A

0DataRank · unranked

19 citations

Caitlin R. Meeker, Elizabeth Handorf, Maureen V. Hill, Margret B. Einarson, R. Katherine Alpaugh +12 more